Hepatic Sinusoidal Obstruction Syndrome in a Patient With Multiple Myeloma Treated With CyBorD.

Tariq, Tooba; Dawdy, John; Goyal, Sachin; Mohamad, Bashar; Singh, Manmeet; Mutchnick, Milton; Ehrinpreis, Murray.

Afiliación

Tariq T; Department of Internal Medicine, Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI.
Dawdy J; Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI.
Goyal S; Department of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI.
Mohamad B; Department of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI.
Singh M; Department of Internal Medicine, Detroit Medical Center/Wayne State University, Detroit, MI.
Mutchnick M; Department of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI.
Ehrinpreis M; Department of Gastroenterology, Detroit Medical Center/Wayne State University, Detroit, MI.

ACG Case Rep J ; 6(7): e00103, 2019 Jul.

Article en En | MEDLINE | ID: mdl-31620512

ABSTRACT

Hepatic sinusoidal obstruction syndrome (SOS) is a life-threatening state generally occurring as a complication of conditioning regimens used for hematopoietic stem cell transplant. Hepatic SOS after a standard dose of chemotherapy in malignancies is rare, and there are only a few cases in pediatric literature. We report a 56-year-old man with multiple myeloma who experienced SOS after being initiated on chemotherapy including cyclophosphamide, dexamethasone, and bortezomib and who experienced a delay in treatment with defibrotide, because it is currently approved by the Food and Drug Administration for only patients who develop SOS after hematopoietic stem cell transplant.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: ACG Case Rep J Año: 2019 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: ACG Case Rep J Año: 2019 Tipo del documento: Article